Journal
IMMUNOTHERAPY
Volume 6, Issue 9, Pages 963-971Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.14.66
Keywords
alpha 4 beta 7-integrin; CD; Crohn's disease; GEMINI; UC; ulcerative colitis; VDZ; vedolizumab
Categories
Funding
- Takeda
Ask authors/readers for more resources
Vedolizumab (VDZ) is a selective antibody against alpha 4 beta 7-integrin, which targets leukocyte trafficking in the gastrointestinal tract. The GEMINI studies are Phase 3, randomized, placebo-controlled trials to assess the efficacy of VDZ in induction and maintenance of moderately to severely active ulcerative colitis (GEMINI 1) and Crohn's disease (GEMINI 2). Included in these studies are patients who have failed TNF-alpha antagonist therapy. GEMINI 1 showed that VDZ is an effective agent in induction and maintenance of ulcerative colitis. GEMINI 2 met one of two primary end points in the induction phase showing that VDZ is more likely to induce clinical remission compared with placebo. VDZ is an effective agent in the maintenance of Crohn's disease. These studies pave the way to a new class of medications for treatment of inflammatory bowel disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available